Kiniksa Pharmaceuticals

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell KNSA and other ETFs, options, and stocks.

About KNSA

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. 

CEO
Sanj K. Patel
CEOSanj K. Patel
Employees
215
Employees215
Headquarters
Lexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded
2015
Founded2015
Employees
215
Employees215

KNSA Key Statistics

Market cap
959.40M
Market cap959.40M
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
349.84K
Average volume349.84K
High today
$14.39
High today$14.39
Low today
$13.27
Low today$13.27
Open price
$14.10
Open price$14.10
Volume
358.27K
Volume358.27K
52 Week high
$15.25
52 Week high$15.25
52 Week low
$7.36
52 Week low$7.36

KNSA News

Simply Wall St 7d
Kiniksa Pharmaceuticals delivers shareholders decent 17% CAGR over 3 years, surging 6.7% in the last week alone - Simply Wall St

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. Just take a...

Kiniksa Pharmaceuticals delivers shareholders decent 17% CAGR over 3 years, surging 6.7% in the last week alone - Simply Wall St

KNSA Earnings

-$0.80
-$0.53
-$0.27
$0.00
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
per share
Estimated per share
Actual
Expected Oct 31, Pre-Market
ActualExpected Oct 31, Pre-Market
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.